Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Athenex Inc (ATNXQ)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
Athenex historical data, for real-time data please try another search
0.015 0.000    0.00%
02/10 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.015 - 0.015
Athenex 0.015 0.000 0.00%

Athenex Inc Company Profile

 
Get an in-depth profile of Athenex Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

275

Equity Type

ORD

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through Oncology Innovation Platform and Commercial Platform segments. The company’s Orascovery product candidates include Oral paclitaxel and encequidar for the treatment of metastatic breast cancer. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company engages in developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinoma. Further, it engages in developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York. On May 14, 2023, Athenex, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on September 12, 2023.

Contact Information

Address Conventus Building Suite 600
1001 Main Street Buffalo, 14203
United States
Phone 716 427 2950
Fax 716 800 6816
Web www.athenex.com
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

ATNXQ Comments

Write your thoughts about Athenex Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Mark Silva
Mark Silva Mar 21, 2023 12:34PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
junk
Reply
0 0
Report
Jamari Tugimin
Jamari Tugimin Feb 06, 2023 6:25PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
ATNX for sure will go up 300 % in one week . Big traders on the roll.
Reply
1 4
Report
Mark Silva
Mark Silva Mar 17, 2022 6:05AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Awful numbers....-20% today for sure
Reply
2 2
Report
Piewhi Van Hirtum
Piewhi Van Hirtum Mar 15, 2022 12:05PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Tomorow big day up?
Reply
1 1
Report
Chris Helm
Chris Helm Mar 07, 2022 12:02PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
So.......8 days from today. What do you think?
Reply
1 1
Report
Chris Helm
Chris Helm Mar 07, 2022 11:02AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
BUFFALO, N.Y., March 07, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the fourth quarter and full year 2021, on Tuesday, March 15, 2022. Athenex’s management team will host a conference call and live audio webcast at 8:00 a.m. Eastern Time.
Reply
0 0
Report
Chris Helm
Chris Helm Mar 04, 2022 3:25PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Earnings announcement* for ATNX: Mar 07, 2022Athenex, Inc. is estimated to report earnings on 03/07/2022. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.04. The reported EPS for the same quarter last year was $-0.53.
Reply
0 0
Report
Piewhi Van Hirtum
Piewhi Van Hirtum Mar 02, 2022 7:26AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
What time the numbers will be relais
Reply
0 0
Report
Piewhi Van Hirtum
Piewhi Van Hirtum Nov 04, 2021 8:16AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Numbers are not good
Reply
0 0
Report
Kim Sant
Kim Sant Oct 26, 2021 6:44PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
P/B could be 1, so at about 1.9$ it will flatten?
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email